David Bupp to Retire from Neoprobe Board of Directors
16 December 2011 - 8:05AM
Business Wire
(NYSE Amex: NEOP) Neoprobe’s Board of Directors today announced
that former President and Chief Executive Officer, David Bupp, will
retire as a Director of Neoprobe Corporation effective January 4,
2012.
“David’s extraordinary vision and commitment to Neoprobe guided
it to its position as one of the world’s most innovative
radiopharmaceutical development companies,” said Gordon Troup,
Chairman of Neoprobe, on behalf of the Board of Directors. “David
has made countless contributions to Neoprobe’s success, and he has
attracted and inspired Neoprobe’s employees and executive team. We
will miss David’s participation in the Board room, but we are
pleased that we will continue to have access to his expertise and
experience through his existing and ongoing consulting agreement
with the Company.”
"Neoprobe has been a major part of my business life for more
than 20 years. Leaving the Board is not a decision that I made
lightly. However, with the recent filing and acceptance for review
of the New Drug Application for Lymphoseek®, the reactivation of
the RIGS® program and now the in-licensing of a new and exciting
product opportunity addressing yet another unmet need in the
Alzheimer’s disease space, Neoprobe’s path forward as a precision
radiopharmaceutical diagnostics company is very clear. I am pleased
with my contributions to those efforts and feel now is an
appropriate time for me to leave the Company as a Director with the
launch of Navidea Biopharmaceuticals," said David Bupp. "I leave
the Company in the hands of a very capable and energetic management
team and Board. I am confident that Neoprobe is poised for the
success I have always known it could achieve.”
About Neoprobe (Navidea Biopharmaceuticals)
Neoprobe Corporation (NYSE Amex: NEOP) is a biopharmaceutical
company focused on the development and commercialization of
precision diagnostics and radiopharmaceutical agents. Neoprobe is
actively developing three radiopharmaceutical agent platforms –
Lymphoseek®, AZD4694 and RIGScanTM CR – to help identify the sites
and pathways of undetected disease and enable better diagnostic
accuracy, clinical decision-making and ultimately patient care.
Neoprobe’s strategy is to deliver superior growth and shareholder
return by bringing to market novel radiopharmaceutical agents and
advancing the Company’s pipeline through selective acquisitions,
global partnering and commercialization efforts. For more
information, please visit www.neoprobe.com.
Neoprobe Corp. Common Stock (AMEX:NEOP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Neoprobe Corp. Common Stock (AMEX:NEOP)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Neoprobe Corp. Common Stock (American Stock Exchange): 0 recent articles
More Neoprobe Corporation News Articles